Special Issues

Special Issue Title: Selected papers from the 2021 AGOA Society

· Print Special Issue Flyer

· Deadline for manuscript submissions: 15 March 2022

Special Issue Editor

Guest Editor

Prof. Dr. Laura Baquedano Mainar

Department of gynecology. Miguel servet university hospital, Spain

Interests: Endometrial Cancer; Menopause; Hormone Replacement Therapy

Special Issue Information

Dear Colleagues,

Every two years, Asociación Aragonesa de Ginecología y Obstetricia (AGOA) organizes a training session to bring together researchers and professionals who work in women's health.
We look forward to receiving your support for this initiative. The objective is to update our knowledge in our area of work and advance in the diagnosis, monitoring and therapy of a variety of diseases and conditions. It is also a good setting to show the lines of research on women's health in our community.

This year the congress will be held from January 28 to April 16, 2021. The most important studies will be presented at the close of the conference in April. This meeting will be supported by the European Journal of Gynaecological Oncology. This is an international journal publishing studies in gynecology oncology.

Prof. Dr. Laura Baquedano Mainar

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250.  Submitted papers should be well formatted and use good English.

Gynecology Oncology; Endometrial Cancer; Ovarian Cancer; Vulvar Cancer; Breast Cancer; Aragón

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
Health related quality of life scales in women diagnosed with gynecological and breast cancer: the role of resilience. A systematic review
Ana Cristina Ruiz Peña, Yasmina José Gutiérrez, Javier Navarro Sierra, Andrea Espiau Romera, Pluvio Coronado Martín, Laura Baquedano Mainar
European Journal of Gynaecological Oncology    2021, 42 (5): 1048-1057.   DOI: 10.31083/j.ejgo4205154
Abstract78)   HTML7)    PDF(pc) (1744KB)(51)       Save

Objective: Resilience and health-related quality of life are factors to be valued today in all types of patients for their relationship to well-being and health. Any stressful situation can significantly impact quality of life and resilience and there are numerous scales to rate these aspects. The main objective of this review is to describe the most used health-related quality of life and resilience scales in gynecological and breast cancer patients to highlight the limitations. Data sources: A review of literature in Pubmed, MEDLINE, Cochrane Database and Google Scholar was carried out to identify articles on health-related quality of life in oncological patients published in English between 2000 and 2020. Methods of study selection: The review was done following the PRISMA guidelines. Tabulation: A total of 460 papers were identified using MeSH terms but finally, according to the inclusion and exclusion criteria, we evaluated 41. Integration and results: Questionnaires have a good performance to quantify quality of life and resilience in oncological patients in general. However, most publications were not focused on patients with gynecological cancer. Conclusions: Due to the particularities of the group of patients with gynecologic and breast cancer secondary to their treatment significantly affecting several areas and domains, it is necessary to validate specific scales for them in order to offer these patients the correct management of their disease at all levels. The role of resilience, premature and iatrogenic menopause and mutilating surgeries are essential to understand the uniqueness of health-related quality of life in gynecological and breast cancer patients.
Related Articles | Metrics
Clinical and demographic factors in endometrial and ovary carcinoma: synchronous carcinoma vs stage IIIA endometrial carcinoma
Laura Baquedano Mainar, Javier Navarro Sierra, Leticia Alvarez Sarrado, Yasmina José Gutiérrez, Marta Lamarca Ballestero, Patricia Rubio Cuesta, Ana C. Ruiz Peña, Andrea Espiau Romera
European Journal of Gynaecological Oncology    2021, 42 (4): 643-648.   DOI: 10.31083/j.ejgo4204099
Abstract116)   HTML7)    PDF(pc) (114KB)(85)       Save

Objective: To compare pre-surgical demographic and clinical factors and preoperative serum tumor marker values of patients with endometrial and ovarian synchronous carcinoma with those diagnosed with endometrial carcinoma with metastatic ovarian involvement (FIGO stage IIIA). Methods: A retrospective observational study including patients with endometrial and ovarian malignant tumors that were treated at Miguel Servet University Hospital, Zaragoza, Spain, since January 2000 to June 2020. All pathologic specimens were reviewed by two pathologists specialized in gynecological oncology. Results: Overall, 51 patients were included. 24 cases of them, were endometrial and ovarian synchronous primary carcinomas and the remaining 27 cases were endometrial tumors with adnexa. Parity, personal and family oncological history, arterial hypertension, diabetes, dyslipidemia, obesity and the prior use of hormone replacement therapy did not show significant differences between both groups. Age (p = 0.002), menopausal status (p = 0.029), abnormal uterine bleeding (p = 0.001), Ca 12.5 preoperative serum level (p = 0.038) and Ca 19.9 preoperative serum level (0.028) were factors with significant differences between both groups. In multivariate analysis, only abnormal uterine bleeding and Ca 19.9 values were independents factors. Conclusions: The presence of abnormal uterine bleeding and Ca 19.9 preoperative serum level could guide the clinician in the preoperative differential diagnosis between endometrial cancer with ovarian involvement and endometrial and ovarian synchronous carcinoma.
Related Articles | Metrics
Effectiveness of the trastuzumab-pertuzumab dual block in neoadjuvance of HER2 positive breast cancer
Ana Cristina Ruiz Peña, Beatriz Domínguez Eguizábal, Susana Marín Alfaro, Cristina Fernández García, Mariano Laguna Olmos, Maria José Puente Martínez
European Journal of Gynaecological Oncology    2021, 42 (4): 721-729.   DOI: 10.31083/j.ejgo4204109
Abstract125)   HTML7)    PDF(pc) (427KB)(81)       Save

Objectives: The combination of trastuzumab and chemotherapy has been the standard neoadjuvant treatment for HER2 positive stages IIA–IIIC breast cancer. However, recent clinical trials support the neoadjuvant use of pertuzumab combined with trastuzumab in conjunction with chemotherapy to improve pathological complete response (pCR) rates. Our main objective was to determine whether the trastuzumab-pertuzumab dual blockade in neoadjuvant HER2-positive breast cancer patients achieves higher rates of pCR relative to patients where only trastuzumab was used. Methods: This was a prospective cohort study in patients at San Pedro’s Hospital in Logroño (Spain) with HER2 positive breast cancer who were candidates for neoadjuvant therapy. 39 patients received dual block treatment and were compared with a non-concurrent (retrospective) control group of 39 patients receiving single block treatment. Results: According to the logit model, the coefficient that relates the probability that the pathological response is complete in the case of dual blockade was positive (2.272) and significant at 1% (p-value less than 0.01). The correlation coefficient between radiological and pathological response was 0.87 when we consider dual block treatment. Mucositis was the most frequent adverse effect (29.49% of the sample). There were 3 cardiac events in the single block group and none in the dual block group. Conclusions: The pCR was greater in the dual block group than in the single block group (69.23% versus 25.64%). There was a greater correlation between radiological and pathological response in dual blockade patients. Safety profile was similar in both groups.

Table and Figures | Reference | Related Articles | Metrics

Current Issue

  • Volume 42, Issue 5